U.S Stocks to Track: Sirius XM Holdings, (NASDAQ:SIRI), Smart & Final Stores (NYSE:SFS), ImmunoGen, (NASDAQ:IMGN), Turkcell Iletisim Hizmetleri A.S. (NYSE:TKC)

U.S Stocks to Track: Sirius XM Holdings, (NASDAQ:SIRI), Smart & Final Stores (NYSE:SFS), ImmunoGen, (NASDAQ:IMGN), Turkcell Iletisim Hizmetleri A.S. (NYSE:TKC)

- in Business & Finance
0

 

Sirius XM Holdings Inc. (NASDAQ:SIRI)

Sirius XM Holdings Inc. (NASDAQ:SIRI), declared the launch of Buying and Selling, a new one-hour show in which Fredrik Eklund, star of Bravo’s Million Dollar Listing New York, will examine the art of buying and selling—almost anything.

Buying and Selling teams Fredrik with his brother, co-host Sigge Eklund, a comedian, author and host of one of the most popular podcasts in Sweden, for this limited-run series on SiriusXM’s Stars channel starting November 20. The Eklund brothers will be joined by a celebrity guest each week for a lively conversation about current deals and successes with buying and selling—in pop-culture, real estate and even their personal lives. Sharing their common obsession with what makes something sellable in today’s world, they will discuss topics ranging from successful selling of a personal brand, a penthouse apartment or the art of selling a story.

“I am beyond excited to host a new show with my brother Sigge on SiriusXM,” said Fredrik Eklund. “This is the perfect platform for us to connect more with fans and each other—sharing our different perspectives and best practices for successful selling of brands.”

Sirius XM Holdings Inc., through its auxiliaries, provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, counting various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic reports for 22 metropolitan markets.

Smart & Final Stores Inc (NYSE:SFS)

On Thursday, Smart & Final Stores Inc (NYSE:SFS)’s shares inclined 11.77% to $16.33.

SFS has 37.80% institutional ownership while its EPS ratio was 0.50. The company has 73.76 million shares outstanding while market capitalization of the company was $1.05 billion. Price to book ratio was 2.22. Net profit margin of the company was 1.00% while gross profit margin was 15.10%. Stock volatility for the month was booked as 5.56% while for the week was recorded as 4.19%.

The mean estimate for the short term price target for Smart & Final Stores Inc (NYSE:SFS) stands at $19.56 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $23.00 while the lower price target estimate is at $18.00.

Analysts mean recommendation for the stock is 2.30. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Smart & Final Stores, Inc. is a food retailer serving household and business customers through two store banners: Smart & Final and Cash & Carry.

ImmunoGen, Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. (NASDAQ:IMGN)’s shares gained 1.18% to $12.81.

IMGN has the market capitalization of $1.09 billion. The stock has P/B ratio of -98.54 while EPS was $-0.84. Institutional ownership of the company was 91.50% while 86.98 million shares were outstanding. Net profit margin of the Company was -82.80%. Share of the company moved above its SMA 50 with 7.65%. ROE ratio was -157.00% while ROI was -155.30%.

The mean estimate for the short term price target for ImmunoGen, Inc. (NASDAQ:IMGN) stands at $15.80 according to 10 Analysts. The higher price target estimate for the stock has been calculated at $24.00 while the lower price target estimate is at $8.00.

Analysts mean recommendation for the stock is 2.40. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company’s clinical and preclinical product candidates are antibody-drug conjugates (ADCs).

Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC)

At the end of Thursday’s trade, Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC)‘s shares surged 1.39% to $10.18.

TKC Its past 5-day performance at 2.72%. So far in 2015, the company has a year-to-date performance of -32.67%. The stock, as of last close, traded 18.93% up from its 52 week low and was -29.71% below its 52 week high. Its latest closing price was -5.65% below the SMA200 while the distance from SMA 50 and SMA 20 was 7.55% and 1.71% respectively.

The mean estimate for the short term price target for Turkcell Iletisim Hizmetleri A.S. (ADR) (NYSE:TKC) stands at $11.80 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $15.40 while the lower price target estimate is at $9.50.

Analysts mean recommendation for the stock is 2.70. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Turkcell Iletisim Hizmetleri A.S. is an integrated communication and technology services provider in Turkey. The Company provides its services through its wholly owned subsidiary, Turkcell Superonline, which offers fixed Internet services.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

Leave a Reply

Your email address will not be published. Required fields are marked *